Therapy News and Research

RSS

St. Jude Medical receives CE Mark approval for Quadra Allure MP CRT-P

St. Jude Medical, Inc., a global medical device company, today announced CE Mark approval of the Quadra Allure MP™ cardiac resynchronization therapy pacemaker (CRT-P).

13 Dec 2014

Study finds that K13 gene mutations cause malaria drug resistance in Southeast Asia

Growing resistance to malaria drugs in Southeast Asia is caused by a single mutated gene inside the disease-causing Plasmodium falciparum parasite, according to a study led by David Fidock, PhD, professor of microbiology & immunology and of medical sciences (in medicine) at Columbia University Medical Center.

12 Dec 2014

Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer.

12 Dec 2014

Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals.

12 Dec 2014

MSU researchers find possible way to boost healthy cell production in cancer patients during chemo

Michigan State University scientists are closer to discovering a possible way to boost healthy cell production in cancer patients as they receive chemotherapy. By adding thymine - a natural building block found in DNA - into normal cells, they found it stimulated gene production and caused them to multiply.

12 Dec 2014

OCT enhances neovascular subtype detection in AMD

Researchers recommend the inclusion of optical coherence tomography anatomic classification with fluorescein angiography grading to identify initial neovascular lesion subtypes in newly diagnosed age-related macular degeneration.

11 Dec 2014

Non-use of bipolar medication typically follows careful ‘risk–benefit’ evaluation

An investigation into why and how patients with bipolar disorder manage their moods without medication has found that most individuals are initially motivated by concerns about side effects.

11 Dec 2014

OncoTherapy Network discusses latest research on prostate cancer

UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest research on prostate cancer.

11 Dec 2014

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.

11 Dec 2014

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.

11 Dec 2014

CVRx gets CE Mark approval to expand labeling of Barostim neo System as MR Conditional

CVRx, Inc., a privately held medical device company, announced today that CE Marking has been granted to expand labeling of the Barostim neo System as MR Conditional, or safe for use in Magnetic Resonance Imaging (MRI) systems under specified conditions.

11 Dec 2014

Two-thirds of U.S. women with early-stage breast cancer receive longer radiation therapy

Two-thirds of women treated for early-stage breast cancer in the U.S. receive longer radiation therapy than necessary, according to a new study published in JAMA this week from Penn Medicine researchers Ezekiel J. Emanuel, MD, PhD, and Justin E. Bekelman, MD.

11 Dec 2014

New therapeutic approach for women with estrogen-receptor-positive breast cancer

Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.

11 Dec 2014

New technique allows rapid, large-scale studies of gene function

Using a gene-editing system originally developed to delete specific genes, MIT researchers have now shown that they can reliably turn on any gene of their choosing in living cells.

11 Dec 2014

CUMC researchers devise way to replace torn knee meniscus

Columbia University Medical Center researchers have devised a way to replace the knee's protective lining, called the meniscus, using a personalized 3D-printed implant, or scaffold, infused with human growth factors that prompt the body to regenerate the lining on its own.

11 Dec 2014

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

11 Dec 2014

$Using Refractory Metals in Cancer Treatments$

Using Refractory Metals in Cancer Treatments

This interview discusses how refractory metals can be used in cancer treatments.

From H.C. Starck Solutions 10 Dec 2014

ECT improves general neurocognitive function in bipolar patients

A randomised trial shows that electroconvulsive therapy improves overall neurocognition in patients with treatment-resistant bipolar depression.

10 Dec 2014

UTHealth opens Trauma and Grief Center for Youth

Children who are having difficulty processing trauma or loss can now turn to the Trauma and Grief Center for Youth at The University of Texas Health Science Center at Houston.

10 Dec 2014

Myriad Genetics highlights three new studies at SABCS 2014

Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.

10 Dec 2014